Andere Sprachen Biora Therapeutics, Inc.

Aktien

A3D3BN

US74319F3055

BIOR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
0,731 ^USD	+2,55 %		+16,46 %	-45,85 %

30.04.	Biora Therapeutics, Inc. gibt den Abschluss der Kohorten mit mehrfach aufsteigender Dosis (Mad) für die klinische Studie von BT-600 bekannt	CI
04.04.	Biora Therapeutics, Inc. erzielt positive Zwischenergebnisse für die klinische Studie von BT-600 und bringt die Entwicklung der NaviCap-Plattform voran	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600	30.04.
Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	30.04.
Biora Therapeutics : Form 8937 – Convertible Note Exchange (December 19, 2023)	11.04.
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology	08.04.
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development	04.04.
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	04.04.
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	03.04.
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	03.04.
Top Midday Decliners	01.04.
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	01.04.
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.03.
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	26.03.
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update	18.03.
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset	11.03.
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600	26.02.
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600	26.02.
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium	08.02.
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.	22.01.
Biora Therapeutics Provides Outlook for 2024	16.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Biora Therapeutics, Inc.

Aktien

A3D3BN

US74319F3055

BIOR

Andere Sprachen

Filter